Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at

SKU: 1047. Categories: , .

Product Description

Named Patient Programs Yield Significant Results

Access to information about drug development and clinical pipelines has become readily available on a worldwide basis. Physicians and patients are now more informed than ever before about innovative drugs in late-stage development, and they are keenly aware of drugs that have been approved in foreign countries but not yet approved in their own. As a result, global demand for innovative medicines in late-stage development or medicines approved in a limited number of countries has grown substantially over the past few years, motivating pharmaceutical and biotechnology companies as well as regulatory bodies to find ways to provide access to these drugs in a controlled, legal, and ethical way. In particular, the robust pipelines of the American companies have attracted a marked increase in requests for these medicines from overseas…